
Trogenix lands $95m Series A, backed by Eli Lilly, for brain cancer therapy
Trogenix has raised £70m ($95m) in Series A financing to help bring its “Trojan horse” cancer treatment into clinical trials, attracting the backing of a big pharma company in the process. Scottish biotech Trogenix is developing a viral immunotherapy …